Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Cancer immunotherapy by delivering class II MHC antigens using a VLP-replicon

A technology of replicon and composition, which is applied in the direction of cancer antigen components, antibody medical components, virus antigen components, etc., and can solve the problems of easy contamination, trouble, too long, etc.

Pending Publication Date: 2021-11-16
UNITED STATES OF AMERICA
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The process is cumbersome, lengthy, and prone to contamination during ex vivo steps

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cancer immunotherapy by delivering class II MHC antigens using a VLP-replicon
  • Cancer immunotherapy by delivering class II MHC antigens using a VLP-replicon
  • Cancer immunotherapy by delivering class II MHC antigens using a VLP-replicon

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0123] Example 1 - Generation of an alphavirus-based gene expression system

[0124] Alphavirus gene expression systems are designed to allow VLP-mediated delivery of exogenous genes of interest (GOIs) or proteins of interest (POIs) to target cells with a low risk of causing cytopathic viral infection. Expression systems were designed using three vectors that can be expressed in packaging cell lines to generate transduced VLPs. One vector encodes an alphavirus-based expression construct, another vector encodes a retroviral gag protein to facilitate VLP formation, and a third vector encodes a fusion protein to mediate fusion of VLPs to host cells. Additionally, the system is constructed to work without the need for the presence of alphavirus structural proteins.

[0125] To accomplish this, an alphavirus-based DNA plasmid was generated with the following: cytomegalovirus promoter (CMV); followed by a retroviral packaging signal for the corresponding retroviral packaging protei...

Embodiment 2

[0131] Example 2 - Expression of various proteins in target cells transduced with VEE VLPs

[0132] The basic concept of RNA delivery using VLPs is shown in figure 2 . In this experiment, a breast cancer model was used. A replicon dual-promoter vector was developed for the expression of HLA-DR1 and CD80 ( image 3 ). 4T1-Luc2 breast cancer cells were infected with VLPs encoding these two antigens. Using anti-HLA-DR and CD80 antibodies, the results show that both proteins are indeed expressed in this cell. HLA-DR1 and CD80 have figure 2 The VLP-VEE replicon was expressed in VLP-transfected 4T1-Luc2 cells. Cells expressing HLA-DR1 were identified by anti-HLA-DR antibody labeled with FITC. Cells expressing CD80 were identified by anti-CD80 antibody labeled with PE.

[0133] To assess whether alphavirus replicons can express two separate proteins in the same cell, VEE replication with HLA-DR1 under the control of one subgenomic promoter and CD80 under the control of the ...

Embodiment 3

[0134] Example 3 - Expression of various proteins in target cells transduced with VEE VLPs

[0135] To test VLPs in a mouse animal system, 4T1-Luc2 cells (highly aggressive and metastatic breast cancer cells) were implanted into the mammary fat pads of 10 mice. Tumors were visible within a few days and became apparent and palpable (5-7 mm) within a week. 3 mice were injected intratumorally with VLPs expressing inert protein (GFP), 2 mice were injected with VLPs expressing human HLA-DR1 / CD80 (allogeneic), and 5 mice were left uninjected as controls.

[0136] After 1 week, tumors were surgically removed from all mice and followed for several weeks for tumor regrowth and metastasis. result( Figure 5) showed that 4 out of 5 uninjected mice (untreated controls) died within 4-6 weeks due to cancer regrowth and metastasis in lung, breast and liver. All 3 mice injected with VLP / GFP (non-specific protein control) also died within 4-6 weeks due to cancer regrowth and metastasis in l...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Described herein is a method of preventing or treating a disease in a mammalian subject, comprising administering to the subject who is in need thereof an effective dosage of a pharmaceutical composition comprising a virus like particle (VLP) comprising: an alphavirus replicon comprising a recombinant polynucleotide, wherein the polynucleotide comprises a sequence encoding both subunits of a human class II major histocompatibility antigen, a retroviral gag protein, and a fusogenic envelope protein, wherein the VLP does not contain an alpha virus structural protein gene.

Description

[0001] This application is a divisional application for an invention patent application with an application date of December 16, 2014, an application number of 201480074163.2, and the title of the invention is "Cancer Immunotherapy for Class II MHC Antigen Delivery by Using VLP Replicons". [0002] CROSS-REFERENCE TO RELATED APPLICATIONS [0003] This application claims the benefit of US Provisional Patent Application no. 61 / 916,394, filed December 16, 2013, under 35 U.S.C. § 119(e), the contents of which are incorporated herein by reference in their entirety. [0004] Field of Invention [0005] The invention described herein relates to the use of replication-defective virus-like particles to deliver and transcribe nucleic acids expressing a major histocompatibility antigen class II to mammals. [0006] Background of the Invention [0007] A major challenge in cancer therapy, especially chemotherapy, is the lack of specificity for target cancer cells, as small molecules are a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/12A61K39/00A61K45/06A61P35/00
CPCA61K39/0011A61K39/12C12N7/00C12N15/86A61K2039/5258A61K2039/53A61K2039/585C12N2740/11023C12N2770/36123C12N2770/36143C12N2770/36145C12N2800/24C12N2810/6081A61K39/001163A61K39/001191A61K39/001144A61K39/001124A61K39/001117A61K39/001181A61K39/001129A61K39/001182A61K39/001194A61K39/001152C12N2770/36134C12N2770/36152C12N2740/11042A61P35/00A61P43/00A61P31/12A61K45/06C12N2770/36171
Inventor D.K.查特吉S.J.卡茨玛茨克
Owner UNITED STATES OF AMERICA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com